breast-cancer
10 stories tagged "breast-cancer"
Norway's Own Screening Adviser Ran the Numbers: About One in 86 Screened Women Overdiagnosed
By its own adviser's estimate, Norway's mammography program overdiagnoses about one in 86 screened women, roughly three for every breast cancer death it prevents, while a 58-trial review finds early detection is no reliable stand-in for fewer deaths.
CancerHengrui's Breast Cancer Drug More Than Doubled Progression-Free Survival While Severe Anemia Hit Four in Ten Patients
Trastuzumab rezetecan pushed median progression-free survival to 16.4 months from 6.8 on chemotherapy in 551 patients, all treated in China, while grade 3 or worse anemia reached 42.8 percent against 4.8 percent.
CancerA 34-Year Mammography Advocate Co-Wrote the Study That Shrinks Screening's Biggest Harm
Overdiagnosis, the risk that screening treats cancers that never would have killed you, was pegged as high as 50 percent. A reinterpretation of eight old trials now puts it under 5, with an author who has promoted screening for 34 years.
CancerThe Women Low on Vitamin D Were Three Times as Likely to Wake From a Mastectomy in Serious Pain
Ninety-two breast cancer patients went into a mastectomy deficient in vitamin D; they were three times as likely to be in serious pain afterward and drew far more from the tramadol pump than the women whose levels were fine.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Its Own Advisers Had Just Rejected, 6 to 3
An FDA advisory panel voted 6 to 3 that AstraZeneca had not shown its breast cancer drug delivered a meaningful benefit. The agency approved it four months later anyway.
CancerThe Breast Cancer Cells That Hide From Chemotherapy Were Already There Before the First Dose
British researchers mapped where dormant breast-tumor cells hide, inside protective pockets of immune and connective cells, and found cells resembling therapy-resistant survivors already parked there before treatment begins.
Drugs & FDAThe FDA Approved a Breast Cancer Drug Four Months After Its Advisers Voted No
On April 30 the FDA's oncology advisers voted 6 to 3 that AstraZeneca's camizestrant hadn't shown a clinically meaningful benefit. On September 4 the agency approved it anyway, conceding in its own approval that the benefit is "not yet confirmed."
CancerThe Cells That Heal Wounds Are Feeding Breast Cancer Its Nerves
University of Oklahoma researchers blocked the protein in mice and triple-negative tumors grew far less. In patients, all they have is a correlation and a drug, already sold for something else, that has never been tried against breast cancer.
CancerPregnancy Stations Killer T Cells in the Milk Ducts, and a Decade Later They Haven't Left
Melbourne researchers found that pregnancy stations killer T cells in the milk ducts, where they persist for at least a decade and track with better breast cancer outcomes. Now the race is on to summon them with a hormone shot instead of a pregnancy.
CancerOzempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past
A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.